Therapeutic role of interleukin-1 receptor antagonist in pancreatic diseases: mendelian randomization study.
acute pancreatitis (AP)
chronic pancreatitis
interleukin-1 receptor antagonist
mendelian randomization
pancreatic cancer
pancreatic disease
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
15
06
2023
accepted:
25
08
2023
medline:
31
10
2023
pubmed:
2
10
2023
entrez:
2
10
2023
Statut:
epublish
Résumé
The interleukin-1 pathway has been linked to pancreatic diseases. We applied the Mendelian randomization approach to explore whether higher interleukin-1 receptor antagonist (IL-1RA) levels reduce the risk of acute and chronic pancreatitis and pancreatic cancer. Genetic variants associated with blood IL-1RA levels at the genome-wide significance level and located 5MB downstream or upstream of the Genetically predicted higher levels of IL-1RA were associated with a lower risk of acute and chronic pancreatitis and pancreatic cancer. In the meta-analysis of UK Biobank and FinnGen, the combined odds ratio was 0.87 (95% confidence interval [CI] 0.77-0.97, This study suggests a protective role of IL-1RA in three major pancreatic diseases, which hints the therapeutic potentials of IL-1RA in pancreatic diseases.
Sections du résumé
Background
The interleukin-1 pathway has been linked to pancreatic diseases. We applied the Mendelian randomization approach to explore whether higher interleukin-1 receptor antagonist (IL-1RA) levels reduce the risk of acute and chronic pancreatitis and pancreatic cancer.
Methods
Genetic variants associated with blood IL-1RA levels at the genome-wide significance level and located 5MB downstream or upstream of the
Results
Genetically predicted higher levels of IL-1RA were associated with a lower risk of acute and chronic pancreatitis and pancreatic cancer. In the meta-analysis of UK Biobank and FinnGen, the combined odds ratio was 0.87 (95% confidence interval [CI] 0.77-0.97,
Conclusion
This study suggests a protective role of IL-1RA in three major pancreatic diseases, which hints the therapeutic potentials of IL-1RA in pancreatic diseases.
Identifiants
pubmed: 37781392
doi: 10.3389/fimmu.2023.1240754
pmc: PMC10538534
doi:
Substances chimiques
Interleukin 1 Receptor Antagonist Protein
0
Receptors, Interleukin-1
0
Types de publication
Meta-Analysis
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1240754Informations de copyright
Copyright © 2023 Yuan, Miao, Ruan, Chen, Li and Larsson.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Genet. 2020 Jun;52(6):634-639
pubmed: 32424355
Clin Cancer Res. 2011 Mar 15;17(6):1502-8
pubmed: 21266527
Diabetes. 2020 Jul;69(7):1588-1596
pubmed: 32349989
Am J Hum Genet. 2018 Nov 1;103(5):691-706
pubmed: 30388399
Nature. 2023 Jan;613(7944):508-518
pubmed: 36653562
Int J Epidemiol. 2017 Dec 1;46(6):1734-1739
pubmed: 28398548
N Engl J Med. 2007 Apr 12;356(15):1517-26
pubmed: 17429083
Gut. 2021 Feb;70(2):330-341
pubmed: 32393543
J Exp Clin Cancer Res. 2016 Jul 29;35(1):122
pubmed: 27473228
Elife. 2023 Feb 02;12:
pubmed: 36727839
NPJ Genom Med. 2021 Mar 29;6(1):27
pubmed: 33782414
Am J Transplant. 2017 Feb;17(2):365-376
pubmed: 27376767
Biochem Pharmacol. 2015 Feb 15;93(4):449-60
pubmed: 25559498
Eur J Epidemiol. 2017 May;32(5):377-389
pubmed: 28527048
Int J Cardiol. 2020 Aug 15;313:99-104
pubmed: 32223966
Scand J Gastroenterol. 2014 Sep;49(9):1124-30
pubmed: 24912987
Biomed Pharmacother. 2012 Mar;66(2):83-8
pubmed: 22281291
J Hematol Oncol. 2022 May 23;15(1):70
pubmed: 35606824
Arthritis Rheumatol. 2022 Oct;74(10):1638-1647
pubmed: 35583917
Cancer Discov. 2016 Aug;6(8):852-69
pubmed: 27246539
Nature. 2014 Feb 20;506(7488):376-81
pubmed: 24390342
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Ann Rheum Dis. 2011 May;70(5):747-54
pubmed: 21173013
Nat Metab. 2020 Oct;2(10):1135-1148
pubmed: 33067605
Nat Genet. 2018 May;50(5):693-698
pubmed: 29686387
Diabetologia. 2006 Sep;49(9):2162-73
pubmed: 16865359
Lancet Diabetes Endocrinol. 2015 Apr;3(4):243-53
pubmed: 25726324
Nat Rev Drug Discov. 2012 Aug;11(8):633-52
pubmed: 22850787
Gastroenterology. 2008 Oct;135(4):1277-87
pubmed: 18789941
Nat Rev Drug Discov. 2011 Jun;10(6):439-52
pubmed: 21629294
Cochrane Database Syst Rev. 2009 Jan 21;(1):CD005121
pubmed: 19160248
PLoS Med. 2015 Mar 31;12(3):e1001779
pubmed: 25826379
Lancet Gastroenterol Hepatol. 2019 Dec;4(12):934-947
pubmed: 31648972
Gastroenterology. 1997 Nov;113(5):1741-6
pubmed: 9352880